ArticleCureus2025
Nivolumab-Induced Fasciitis Mimicking Scleroderma: A Diagnostic Challenge.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immune checkpoint inhibitor-induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force study.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 74-year-old male on nivolumab for desmoplastic melanoma developed progressive skin tightening, woody induration, and restricted mobility, initially suggestive of systemic sclerosis. He lacked classic scleroderma features (e.g., Raynaud's, digital ulcers) but had eosinophilia (1100 cells/µL) and antinuclear antibody (ANA)/ ribonucleoprotein (RNP) positivity. MRI confirmed eosinophilic fasciitis (EF), prompting discontinuation of nivolumab and initiation of high-dose corticosteroids and mycophenolate, leading to gradual improvement over six months. This case highlights the diagnostic overlap between immune checkpoint inhibitor (ICI)-induced scleroderma-like syndrome and EF, emphasizing the need for early recognition and tailored immunosuppression to mitigate immune-related adverse events (irAEs) while balancing cancer therapy. Awareness of atypical presentations (e.g., hand/face involvement in EF) is critical for timely intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.